Testing Olpasiran against a placebo for cardiovascular disease
Official title: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
- Phase 3
- 2 groups
- Sites in Calgary, Edmonton and 17 more cities
- Recruiting
Interventions
- Medication
Olpasiran
Olpasiran will be administered via SC injection.
- Medication
Placebo
Placebo will be administered via SC injection.
Canadian Sites (25)
24 of 25 recruiting
- Recruiting
Centricity Research Calgary
Calgary, Alberta
- Recruiting
Edmonton Cardiology Consultants
Edmonton, Alberta
- Recruiting
Fraser Clinical Trials
New Westminster, British Columbia
- Recruiting
SMH Cardiology Clinical Trials Incorporated
Surrey, British Columbia
- Recruiting
ARC Biosystems Incorporated
Vancouver, British Columbia
- Recruiting
Victoria Heart Institute Foundation
Victoria, British Columbia
- Recruiting
Discovery Clinical Services Ltd
Victoria, British Columbia
- Recruiting
Centricity Research Brampton
Brampton, Ontario
- Recruiting
Circulate Cardiac & Vascular Centre
Burlington, Ontario
- Recruiting
Cambridge Cardiac Care Centre
Cambridge, Ontario
- Recruiting
Hamilton Health Sciences Hamilton General Hospital
Hamilton, Ontario
- Recruiting
St Josephs Hospital
London, Ontario
- Recruiting
Elevate Clinical Research KMH Missisauga
Mississauga, Ontario
- Recruiting
Partners in Advanced Cardiac Evaluation
Newmarket, Ontario
- Recruiting
North York Diagnostic and Cardiac Centre
North York, Ontario
- Recruiting
Oakville Cardiovascular Research
Oakville, Ontario
- Recruiting
Heart Health Institute Research Incorporated
Scarborough Village, Ontario
- Recruiting
Womens College Hospital
Toronto, Ontario
- Recruiting
Ecogene-21
Chicoutimi, Quebec
- Recruiting
Montreal Heart Institute
Montreal, Quebec
- Recruiting
Institut de recherches cliniques de Montreal
Montreal, Quebec
- Recruiting
Centre de Recherche du Centre Hospitalier de l Universite de Montreal
Montreal, Quebec
- Recruiting
Research Institute of McGill University Health Center - Glen Site
Montreal, Quebec
- Recruiting
CIUSSS de l Estrie CHUS Hopital Fleurimont
Sherbrooke, Quebec
- Completed
Premier Clinical Trial Network
Hamilton, Ontario
Eligibility Criteria
See who this study is looking for6 criteria
The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.
Inclusion
- +Age ≥50 years
- +Lp(a)≥ 200 nmol/L during screeningScreeningThe checks done before joining, to see whether a study fits.Read more →
- +Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
Exclusion
- −Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
- −Prior or planned arterial revascularization
- −History of major bleeding disorder
In plain language
Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.
What this study is
This study is testing a treatment for a condition.
Phase 3Phase 3A large study comparing a treatment against the current standard.Read more → — a large study comparing this against the current standard, usually across many hospitals.
From the trial registry
Built from these fields:
- designModule.designInfo.primaryPurpose
- designModule.phases
Who receives what
There are 2 groups in this study.
Group A receives Olpasiran.
Registry label: A: Olpasiran
Group B, the placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group, receives Placebo.
Registry label: B: Placebo
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].label
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
How the study is run
Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.
Neither you nor the study team would know which group you are in until the study ends.
From the trial registry
Built from these fields:
- designModule.designInfo.allocation
- designModule.designInfo.maskingInfo.masking
Is there a placebo?
One group receives a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → — a dummy treatment with no active medicine in it.
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for
The study lists an age range of 50 years to 105 years.
The study is open to people of any sex.
The study does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.
From the trial registry
Built from these fields:
- eligibilityModule.minimumAge
- eligibilityModule.maximumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How big and how long
The study aims to enrol about 11,000 people.
The study is currently expected to finish around October 2031.
The main measurement is taken over: Up to approximately 6.2 years.
From the trial registry
Built from these fields:
- designModule.enrollmentInfo.count
- statusModule.completionDateStruct.date
- outcomesModule.primaryOutcomes[].timeFrame
What the study measures
Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs First — measured over Up to approximately 6.2 years.
From the trial registry
Built from these fields:
- outcomesModule.primaryOutcomes[].measure
- outcomesModule.primaryOutcomes[].timeFrame
Source: NCT07136012 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.
Not medical advice. What do these terms mean?
What is being tested — in plain terms
About OlpasiranDrug
Olpasiran will be administered via SC injection.
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About PlaceboDrug
Placebo will be administered via SC injection.
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
Common questions
Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.
Am I eligible for this trial?
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.
What the study lists: an age range of 50 years to 105 years.
The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.
The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.maximumAge
- eligibilityModule.eligibilityCriteria
Is there a placebo?
Yes. This study includes a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group — a dummy treatment with no active medicine in it.
From the trial registry
- armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?
Neither you nor the study team would know which group you are in until the study ends.
Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.
From the trial registry
- designModule.designInfo.maskingInfo.masking
- designModule.designInfo.allocation
Who can join?
The study lists an age range of 50 years to 105 years.
It is open to people of any sex.
It does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.maximumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How long would this take?
The study's main measurement is taken over: Up to approximately 6.2 years.
The study as a whole is currently expected to finish around 2031-10-20.
How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.
From the trial registry
- outcomesModule.primaryOutcomes[].timeFrame
- statusModule.completionDateStruct.date
How many people are taking part?
The study aims to enrol about 11,000 people.
From the trial registry
- designModule.enrollmentInfo.count
Where is this happening?
This study lists 41 locations, including: Calgary, Alberta, Canada; Edmonton, Alberta, Canada; New Westminster, British Columbia, Canada; Surrey, British Columbia, Canada; Vancouver, British Columbia, Canada; Victoria, British Columbia, Canada, and 35 more.
Sites can open and close during a study, so confirm with the team before travelling.
From the trial registry
- trial_locations
About This Trial
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
Other Sites (23)
Henry Ford Health System
Detroit, Michigan, United States
Healthy Heart Cardiology
Grand Rapids, Michigan, United States
MyMichigan Medical Center Midland - Clinical Research Department
Midland, Michigan, United States
Advanced Cardiology Associates
Rochester Hills, Michigan, United States
Revival Research Institute
Southfield, Michigan, United States
Saint Marys Medical Center
Duluth, Minnesota, United States
Health East Cancer Care
Maplewood, Minnesota, United States
University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Methodist Hospital
Saint Louis Park, Minnesota, United States
Albany Medical College
Albany, New York, United States
Basil Clinical
Inwood, New York, United States
Rasai Research
Jackson Heights, New York, United States
Crystal Run Healthcare
Monroe, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Mount Sinai Queens
New York, New York, United States
Ima Clinical Research Manhattan
New York, New York, United States
Niagara Falls Memorial Medical Center
Niagara Falls, New York, United States
Circuit Clinical Orchard Park Family Practice
Orchard Park, New York, United States
Hudson Valley Cardiovascular Physicians PC
Poughkeepsie, New York, United States
And 3 more sites worldwide.
Think this trial might be right for you?
Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.
See if this trial could fit youThis page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.